Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control
- PMID: 22553309
- PMCID: PMC11104196
- DOI: 10.1177/1098612X12446211
Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control
Abstract
The aim of this study was to report outcomes using detemir and a protocol aimed at intensive blood glucose control with home monitoring in diabetic cats, and to compare the results with a previous study using the same protocol with glargine. Eighteen cats diagnosed with diabetes and previously treated with other insulins were included in the study. Data was provided by owners who joined the online German Diabetes-Katzen Forum. The overall remission rate was 67%. For cats that began the protocol before or after 6 months of diagnosis, remission rates were 81% and 42%, respectively (P = 0.14). No significant differences were identified between the outcomes for the glargine and detemir studies, with the exception of three possibly interrelated factors: a slightly older median age of the detemir cohort at diabetes diagnosis, a higher rate of chronic renal disease in the detemir cohort and lower maximal dose for insulin detemir.
Conflict of interest statement
The authors do not have any potential conflicts of interest to declare.
References
-
- Triplitt CL. New technologies and therapies in the management of diabetes. The Am J Manage Care 2007; 13 (Suppl 2): S47–S54. - PubMed
-
- Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol 2010; 47: 271–278. - PubMed
-
- Boari A, Aste G, Rocconi F, et al.. Glargine insulin and high-protein-low-carbohydrate diet in cats with diabetes mellitus. Vet Res Comm 2008; 32 (Suppl 1): S243–S245. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous